CMO-Initiated Recalls Raise Red Flags On Choosing Manufacturing Partner
This article was originally published in The Tan Sheet
Executive Summary
The steady number of CMO-initiated recalls shows manufacturing quality issues are not going away soon, says an FDA Office of Manufacturing and Product Quality official. CMOs have initiated 250 recall events in 2014, up from the 168 they initiated in all of 2007.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.